Regenxbio, a biotechnology firm, and Nippon Shinyaku have entered a partnership to develop and commercialise RGX-11, a drug for the treatment of MPS diseases targeted at Mucopolysaccharides II (MPS II), also known as Hunter Syndrome, and RGX-111, also known as Hurler Syndrome.

The agreement will see Regenxbio receive $110 million upon the deal’s closure, which is expected to be finalised by the end of the first quarter of this year, as well as an additional $700 million in potential milestone payments. It will also be eligible for royalties on net sales in both Asia and the U.S (the ‘Licensed Territory).

The partnership involves Nippon Shinyaku in the commercialisation of both treatments within the Licensed Territory, while Regenxbio will be responsible for further clinical developments. The manufacture of both products will be led by Regenxbio for supply inside the Territory, with rights reserved to develop and commercialise the treatments outside of the Territory.